tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Bersztel A et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. 1995 Transplant. Proc. pmid:8540095
Jonas S et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. 1995 Clin Transplant pmid:8541635
Andoh TF et al. Functional and structural characteristics of experimental FK 506 nephrotoxicity. 1995 Clin. Exp. Pharmacol. Physiol. pmid:8542679
Fukunaga T et al. Osteogenesis in xenogeneic bone transplantation, using an immunosuppressant. Rabbit-rat experiments. 1995 Acta Orthop Scand pmid:8553828
Ryffel B et al. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation. 1995 Immunopharmacology pmid:8557519
Chaudhuri B et al. The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506. 1995 FEBS Lett. pmid:7528690
Sandborn WJ et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. 1995 Hepatology pmid:7528712
Coghlan VM et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. 1995 Science pmid:7528941
Marx SO et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. 1995 Circ. Res. pmid:7532117
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Mor E et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. 1995 Transplant. Proc. pmid:7533363
Hemenway CS et al. vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. 1995 Genetics pmid:8582630
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Gonschior AK et al. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. 1995 Ther Drug Monit pmid:8585114
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Büttemeyer R et al. Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. 1995 Ann Plast Surg pmid:8585683
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Takeda Y et al. Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. 1995 J. Cardiovasc. Pharmacol. pmid:8587392
O'Rourke M et al. Recovery of delayed-type hypersensitivity following liver transplantation. 1995 Transplant. Proc. pmid:7533369
Goodall T et al. FK506-induced endothelin release by cultured rat mesangial cells. 1995 J. Cardiovasc. Pharmacol. pmid:8587453
Chakraborty TK et al. Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand. 1995 Chem. Biol. pmid:9383417
Saito S et al. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. 1995 Transplant. Proc. pmid:7533420
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Kumano K et al. Role of endothelin in FK 506-induced renal hypoperfusion in rats. 1995 Transplant. Proc. pmid:7533423
Izutani H et al. Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. 1995 Transplant. Proc. pmid:7533425
Bakhtiar R and Stearns RA Studies on non-covalent associations of immunosuppressive drugs with serum albumin using pneumatically assisted electrospray ionization mass spectrometry. 1995 Rapid Commun. Mass Spectrom. pmid:7535601
Ikeda H and Fujiwara K Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. 1995 Hepatology pmid:7535735
Grimmond S et al. Exclusion of the 13-kDa rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1. 1995 Hum. Genet. pmid:7535744
Jiang H et al. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. 1995 J. Invest. Dermatol. pmid:7535825
Atkison P et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. 1995 Lancet pmid:7535875
Winkler M and Christians U A risk-benefit assessment of tacrolimus in transplantation. 1995 Drug Saf pmid:7545405
Ockenfels HM et al. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. 1995 Arch. Dermatol. Res. pmid:7541191
Victor RG et al. Presynaptic modulation of cortical synaptic activity by calcineurin. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7541535
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
McDiarmid SV et al. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients. 1995 J. Pediatr. Gastroenterol. Nutr. pmid:7541834
MacDonald AS and Sketris IS Tacrolimus in transplantation. 1995 Am J Health Syst Pharm pmid:7552906
Holmes JA and Twentyman PR The activity of deoxyspergualin in multidrug-resistant cells. 1995 Cancer Chemother. Pharmacol. pmid:7554042
Elitsur Y et al. FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system. 1995 Dig. Dis. Sci. pmid:7555446
Kobayashi I et al. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. 1995 Eur. J. Pediatr. pmid:7556338
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Adachi M et al. IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. 1995 FEBS Lett. pmid:7556630
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
David M et al. [Occurrence of suspicious changes in cervix cytology in women after liver transplantation]. 1995 Geburtshilfe Frauenheilkd pmid:7557217
Woodle ES et al. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. 1995 Clin Transplant pmid:7537988
Mills RA et al. Topical FK-506 prevents experimental corneal allograft rejection. 1995 Cornea pmid:7538061
Lee TK et al. Postoperative selective bowel decontamination prevents gram-negative bacterial translocation in small-bowel graft recipients. 1995 J. Surg. Res. pmid:7538186
Galat A and Metcalfe SM Peptidylproline cis/trans isomerases. 1995 Prog. Biophys. Mol. Biol. pmid:7538221
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Ishikawa A et al. [A case of tacrolimus-induced glucose intolerance following renal allografting]. 1995 Hinyokika Kiyo pmid:7544064
Lochmüller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. 1995 Biochem. Biophys. Res. Commun. pmid:7544122
Deschler DG et al. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. 1995 Arch. Otolaryngol. Head Neck Surg. pmid:7544136
Zweifach A and Lewis RS Slow calcium-dependent inactivation of depletion-activated calcium current. Store-dependent and -independent mechanisms. 1995 J. Biol. Chem. pmid:7540169
Rouvière-Fourmy N et al. 1H and 15N assignment of NMR spectrum, secondary structure and global folding of the immunophilin-like domain of the 59-kDa FK506-binding protein. 1995 Eur. J. Biochem. pmid:7544285
Brand PL and Brus F Immunosuppressive drugs and hypertrophic cardiomyopathy. 1995 Lancet pmid:7540240
Natazuka T et al. Immunosuppressive drugs and hypertrophic cardiomyopathy. 1995 Lancet pmid:7540241
Dhawan A et al. Immunosuppressive drugs and hypertrophic cardiomyopathy. 1995 Lancet pmid:7540242
Nielsen FT et al. Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. 1995 Nephrol. Dial. Transplant. pmid:7540737
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Okamoto M et al. In situ proliferating status of mononuclear cells in rat small bowel grafts. 1995 Int J Exp Pathol pmid:7547442
Sakane T et al. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. 1995 Ryumachi pmid:8594659
Hammond TG and Kind CN Pancreatic and nephrotoxicity of immunomodulator compounds. 1995 Toxicol. Lett. pmid:8597171
Ma J et al. Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. 1995 Biophys. J. pmid:8599646
Díaz M et al. [Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)]. 1995 Apr-Jun Rev Med Univ Navarra pmid:7569553
Hisatomi K et al. Effect of dose of cyclosporine or FK506 and antithrombotic agents on cardiac allograft vascular disease in heterotopically transplanted hearts in rats. 1995 Jan-Feb J. Heart Lung Transplant. pmid:7537098
Díaz M et al. [Tacrolimus (FK 506): immunosuppressive alternative to solid organ transplant (Part 1)]. 1995 Jan-Mar Rev Med Univ Navarra pmid:14735715
Kawahara K et al. Effects of deoxyspergualin on bronchial anastomosis healing in canine pulmonary allografts. 1995 Jul-Aug J. Heart Lung Transplant. pmid:7578196
Motoyama K et al. Pretransplant intrathymic inoculation of donor antigen combined with FK506 treatment: prolongation of survival of cardiac, but not renal, allografts in rats. 1995 Mar-Apr World J Surg pmid:7538717
Okudaira H et al. Enhanced production and gene expression of interleukin-5 in patients with bronchial asthma: possible management of atopic diseases by down-regulation of interleukin-5 gene transcription. 1995 May-Jun Int. Arch. Allergy Immunol. pmid:7542077
Su Q et al. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. 1995 May-Jun Ren. Physiol. Biochem. pmid:7542793
Hayashi S et al. Evidence that donor pretreatment with FK506 has a synergistic effect on graft prolongation in hamster-to-rat heart xenotransplantation. 1995 May-Jun J. Heart Lung Transplant. pmid:7544621
Castillo Lugo JA Clinical and experimental immunosuppression. 1995 May-Jun Bol Asoc Med P R pmid:8573248
Seifeldin R Drug interactions in transplantation. 1995 Nov-Dec Clin Ther pmid:8750397
Schreiber SL and Crabtree GR Immunophilins, ligands, and the control of signal transduction. 1995-1996 Harvey Lect. pmid:9127988
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Dmitrewski J et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. 1996 J. Hepatol. pmid:8778189
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Cohen DS et al. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy. 1996 Transplant. Proc. pmid:8907923
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Jonas S et al. Conversion to tacrolimus after liver transplantation. 1996 Transpl. Int. pmid:8748407
Rambusch EG and Manns MP [Therapy of autoimmune hepatitis]. 1996 Dtsch. Med. Wochenschr. pmid:8998922
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Lamb GD and Stephenson DG Effects of FK506 and rapamycin on excitation-contraction coupling in skeletal muscle fibres of the rat. 1996 J. Physiol. (Lond.) pmid:8842013
Fealy MJ and Press BH Pinpointing the moment of allograft rejection. 1996 J Hand Surg Am pmid:8724501
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Ezeamuzie CI Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. 1996 Int. J. Immunopharmacol. pmid:8894806
Yagita Y et al. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. 1996 Life Sci. pmid:8913329
Wang X et al. Rapamycin inhibits aldolase A expression during human lymphocyte activation. 1996 J. Cell. Biochem. pmid:8913875
Soubrane O and Houssin D [Liver transplantation. Current aspects]. 1996 Presse Med pmid:8728904
Lampen A et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. 1996 Br. J. Pharmacol. pmid:8732283
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635